Login to Your Account

Complera Nod Bridges Gilead's HIV Franchise; All Eyes on Quad

By Jennifer Boggs

Friday, August 12, 2011
Gilead Sciences Inc.'s Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) won FDA approval as expected, but the single-tablet formulation nicknamed "Btripla" likely will prove only a modest addition to the firm's HIV franchise should the highly anticipated Quad regimen yield strong Phase III data later this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription